PATIENT DRIVEN DESIGN

ADAPT randomized, double-blind, placebo controlled, multicenter Phase 3 study to evaluate the efficacy, safety and tolerability of an investigational drug called efgartigimod in patients with generalized MG (gMG).

The ADAPT clinical study was designed with input from patients and expert clinicians.

When asked, patients requested:

ADAPT Study Design:

A study open to a broad range of patients

Patients who test positive for antibodies (AChR, MuSK, or LRP4) and those who test negative for antibodies (seronegative) may be eligible to participate. This is the first phase 3 study for gMG to include seronegative patients.

A therapy designed to target the underlying cause of gMG

Efgartigimod is thought to reduce the presence of antibodies that contribute to neuromuscular weakness in gMG.

To remain on current medications throughout the study

Efgartigimod or placebo will be administered on top of current gMG medications*.

Treatment that accounts for patient’s specific requirements/ needs

Study drug will be given based on physician evaluation of your individual symptoms.